Preliminary inference was that the mice were treated in the early stage of tumor growth, which led to the complete elimination of tumors in the AXL-CART cell group, thus the enhanced AXL-CART cells failed to show significantly enhanced antitumor activity. This evidence concerns the gene AXL and neoplasm.